BVS on Nasdaq

Bioventus Inc.

Price unavailable

Last updated Oct 16, 2026.

Overview

$568.1MRevenue, fiscal 20252
$22.7MNet income, fiscal 20252

Compare with UFP Technologies, AtriCure (United States) or GLAUKOS Corp, or pick any stock.

  • TickerBVS on Nasdaq
  • IndustrySurgical & Medical Instruments & Apparatus
  • HeadquartersDE
  • Incorporated inDE3
  • Business address4721 Emperor Boulevard, Suite 100, Durham, Nc 277033
  • Filer categoryAccelerated filer, Emerging growth company3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

68.3%Gross margin2
9.5%Operating margin2
4.0%Net margin2
-0.9%Revenue growth, 20252
12.3%Return on equity2
1.52×Debt to equity2
$72.1MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue32¢$179.9M
  • Research and development2¢$12.1M
  • Selling, general and admin55¢$314.0M
  • Other costs7¢$37.7M
  • Income tax0¢$1.6M
  • Profit4¢$22.7M

Out of $568.1M in revenue.2

Where each dollar of operating cash went, fiscal 2025

  • Capital spending3¢$2.6M
  • Kept or used elsewhere97¢$72.1M

Out of $74.7M of cash from operations.2

Financial statements

Revenue45672$568.1M in 2025+67% since 2019
0$200.0M$400.0M$600.0M2019: $340.1M$340.1M20192020: $321.2M$321.2M2020−6%2021: $430.9M$430.9M2021+34%2022: $512.1M$512.1M2022+19%2023: $512.3M$512.3M2023+0%2024: $573.3M$573.3M2024+12%2025: $568.1M$568.1M2025−1%
Gross profit45672$388.2M in 2025+56% since 2019
0$100.0M$200.0M$300.0M$400.0M2019: $249.2M$249.2M20192020: $233.5M$233.5M2020−6%2021: $302.7M$302.7M2021+30%2022: $331.1M$331.1M2022+9%2023: $328.2M$328.2M2023−1%2024: $388.2M$388.2M2024+18%2025: $388.2M$388.2M2025−0%
Operating income45672$54.0M in 2025+73% since 2019
-$200.0M-$100.0M0$100.0M2019: $31.2M$31.2M20192020: $21.2M$21.2M2020−32%2021: $12.1M$12.1M2021−43%2022: -$167.2M-$167.2M20222023: -$81.7M-$81.7M2023−51%2024: -$15.2M-$15.2M2024−81%2025: $54.0M$54.0M2025
Net income45672$22.7M in 2025+232% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M0$50.0M2019: $6.9M$6.9M20192020: $16.4M$16.4M2020+140%2021: $19.4M$19.4M2021+18%2022: -$158.7M-$158.7M20222023: -$156.2M-$156.2M2023−2%2024: -$36.1M-$36.1M2024−77%2025: $22.7M$22.7M2025
Fiscal year20182019202020212022202320242025
Revenue$340.1M4$321.2M5$430.9M6$512.1M7$512.3M2$573.3M2$568.1M2
Cost of revenue$90.9M4$87.6M5$128.2M6$181.0M7$184.2M2$185.1M2$179.9M2
Gross profit$249.2M4$233.5M5$302.7M6$331.1M7$328.2M2$388.2M2$388.2M2
Research and development$11.1M4$11.2M5$19.0M6$23.9M7$13.4M2$14.0M2$12.1M2
Selling, general and admin$198.5M4$193.1M5$254.3M6$332.1M7$303.9M2$343.8M2$314.0M2
Operating income$31.2M4$21.2M5$12.1M6-$167.2M7-$81.7M2-$15.2M2$54.0M2
Income tax$1.6M4$1.2M5-$2.0M6-$44.4M7$85.0K2-$5.3M2-$1.6M2
Net income$6.9M4$16.4M5$19.4M6-$158.7M7-$156.2M2-$36.1M2$22.7M2
Earnings per share-$0.156-$2.597-$2.492-$0.562$0.342
Earnings per share (diluted)-$0.156-$2.597-$2.492-$0.562$0.332

Compare Bioventus Inc. with another company

Recent filings

  1. Aug 5, 20268-K
  2. Aug 5, 202610-Q
  3. Jul 27, 2026SCHEDULE 13G
  4. Jun 4, 20268-K
  5. Jun 4, 20264
  6. Jun 4, 20264
  7. Jun 4, 20264
  8. Jun 4, 20264
  9. Jun 4, 20264
  10. Jun 4, 20264
  11. Jun 4, 20264
  12. Jun 4, 20264
  13. Jun 4, 20264
  14. Jun 4, 20264
  15. May 29, 2026SD

Every filing from the last three years, summarized. The full record is on SEC EDGAR.1